Article
Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response.
Oncotarget - 1 Sept 2012
McCubrey James A, Steelman Linda S, Chappell William H, Abrams Stephen L, Montalto Giuseppe, Cervello Melchiorre, Nicoletti Ferdinando, Fagone Paolo, Malaponte Grazia, Mazzarino Maria C, Candido Saverio, Libra Massimo, Bäsecke Jörg, Mijatovic Sanja, Maksimovic-Ivanic Danijela, Milella Michele, Tafuri Agostino, Cocco Lucio, Evangelisti Camilla, Chiarini Francesca, Martelli Alberto M
Abstract excerpt
The Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades are often activated by genetic alterations in upstream signaling molecules such as receptor tyrosine kinases (RTK). Certain components of these pathways, RAS, NF1, BRAF, MEK1, DUSP5, PP2A, PIK3CA, PIK3R1, PIK3R4, PIK3R5, IRS4, AKT, NFKB1, MTOR, PTEN, TSC1, and TSC2 may also be activated/inactivated by mutations or epigenetic silencing. Upstream mutations in one...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.